Abstract:Background: It has been reported that PKC theta plays an important role in the immune response by regulating the cellular activity of T cells and, thus, the production of immune factors such as IL-2.PKC theta protein is mainly expressed in T lymphocytes but not much in other cells and has a very good specificity. Therefore, it is very meaningful to use PKC theta protein as a novel target for immunosuppression. PKC theta is a valuable target that can be used to develop meaningful novel selective immunosuppressive agents. Methods: In this study, we constructed a 3-characteristic pharmacophoreRHAand used it to perform a virtual screening of the database. Then, we performed a molecular docking analysis of the compounds that scored high. The top five compounds with molecular docking scores were used as lead compounds, and structure-based ligand design via fragment substitution was applied to them, resulting in 20077 new compounds. We performed molecular docking analysis, binding free energy calculations, molecular dynamics simulation, and ADMET prediction on these new compounds and finally identified two compounds as new PKC theta inhibitors. Results and Discussions: Through the screening of pharmacophore, molecular design based on fragment substitution, molecular docking, we finally obtained two small molecules with higher scores than the positive control, in which the molecular docking score of P01 was -53.88 kcal/mol, and the molecular docking score of P02 was -51.20 kcal/mol, and then we performed the molecular dynamics simulation, free energy of binding calculations, and the prediction of ADMET properties for the compounds. The results showed that the ligands could form more stable complexes with the proteins, the binding free energy calculations of the ligand molecules were better than the positive control, all of them had good ADMET properties, and the compounds all had good drug similarity. Conclusion: Our results provided 2 new ligands that could serve as lead compounds for new PKC theta inhibitors in the future.

Insights into the structural requirements of PKC inhibitors as potential anti-arthritis agents based on 3D-QSAR, homology modeling and docking approach

Insights into the structural requirements of PKCζ inhibitors as potential anti-arthritis agents based on 3D-QSAR, homology modeling and docking approach

Exploring the Structure Requirement for PKCθ Inhibitory Activity of Pyridinecarbonitrile Derivatives: an in Silico Analysis.

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations

Combined Pharmacophore Modeling, Docking, And 3d-Qsar Studies Of Plk1 Inhibitors

3D-QSAR, Docking, and Molecular Dynamics Simulations Studies on Quinazoline Derivatives As PAK4 Inhibitors

3d-Qsar And Molecular Docking Studies On Fused Pyrazoles As P38 Alpha Mitogen-Activated Protein Kinase Inhibitors

3D-QSAR Studies on a Series of Inhibitors Docked into a New Homology Model of the DNA-PK Receptor.

3d-Qsar Analysis On Pyrrolopyridine Analogs As Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (Mk-2) Inhibitors

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

3D-QSAR study of c-Src kinase inhibitors based on docking

Identify promising IKK-β inhibitors: A docking-based 3D-QSAR study combining molecular design and molecular dynamics simulation

Applications of 3D-QSAR and Structure-Based Pharmacophore Modeling, Virtual Screening, ADMET, and Molecular Docking of Putative MAPKAP-K2 (MK2) Inhibitors

Target based structural optimization of substituted pyrazolopyrimidine analogues as inhibitor for IRAK4 by 3D-QSAR and molecular simulation

3D‐QSAR and Docking Studies of Quinazoline Derivatives with the Inhibitory Activity Toward NF‐κB

In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives

Structural Requirements of Isoquinolones As Novel Selective C-Jun N-terminal Kinase 1 Inhibitors: 2D and 3D QSAR Analyses.

Structural Determinants Of Cx-4945 Derivatives As Protein Kinase Ck2 Inhibitors: A Computational Study

QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and dynamics study

3D-QSAR and Molecular Docking Studies of ATP-competitive Akt Inhibitors with the Scaffold 4-(Piperazin-1-yl)pyrimidine